Surgeon Experience as a Risk Factor for Short-term Failure for Ab-interno Gelatin Microstent: A Canadian Multicentre Propensity Matched Study

2021 ◽  
Author(s):  
Matthew B. Schlenker ◽  
Jeb Alden Ong ◽  
Pearson Wu ◽  
Delan Jinapriya ◽  
Barend Zack ◽  
...  
Keyword(s):  
Risk Factor ◽  
Short Term ◽  
Surgeon Experience ◽  
Matched Study ◽  
Ab Interno

Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease

2020 ◽  
Vol 27 ◽  
Author(s):  
Keng Yoon Yeong ◽  
Christine Law
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Literature Review ◽  
Neurodegenerative Disorder ◽  
Antihypertensive Drugs ◽  
Future Prospects ◽  
Short Term

Alzheimer’s disease (AD) is a neurodegenerative disorder that has affected millions of people worldwide. However, currently there is no treatment to cure the disease. The AD drugs available in the market only manage the disease symptomatically and the effects are usually short-term. Thus, there is a need to look at alternatives AD therapies. Mid-life hypertension has not only been recognised as a risk factor for AD, but its relation with AD has also been well established. Thus, antihypertensives are postulated to be beneficial in managing AD. This literature review aims to shed some light on the potential of repurposing antihypertensives to treat AD, considering recent updates. Four classes of antihypertensives, as well as their potential limitations and future prospects in being utilised as AD therapeutics are discussed in this review.

scholarly journals Shades between Black and Green Investment: Balance or Imbalance?

2021 ◽  
Vol 13 (9) ◽  
pp. 5024
Author(s):  
 Vítor Manuel de Sousa Gabriel ◽  
María Mar Miralles-Quirós ◽  
José Luis Miralles-Quirós
Keyword(s):  
Risk Factor ◽  
Oil Prices ◽  
Oil Price ◽  
Short Term ◽  
Environmental Indices ◽  
Long Run ◽  
Green Investment ◽  
Bounds Test

This paper analyses the links established between environmental indices and the oil price adopting a double perspective, long-term and short-term relationships. For that purpose, we employ the Bounds Test and bivariate conditional heteroscedasticity models. In the long run, the pattern of behaviour of environmental indices clearly differed from that of the oil prices, and it was not possible to identify cointegrating vectors. In the short-term, it was possible to conclude that, in contemporaneous terms, the variables studied tended to follow similar paths. When the lag of the oil price variable was considered, the impacts produced on the stock market sectors were partially of a negative nature, which allows us to suppose that this variable plays the role of a risk factor for environmental investment.

BactDNA as an Independent Risk Factor for Short-Term Crohn’s Disease Recurrence

2016 ◽  
Vol 111 (10) ◽  
pp. 1500-1501
Author(s):  
Alessandro Sartini ◽  
Maria Chiara Verga ◽  
Luca Marzi ◽  
Nicola De Maria ◽  
Erica Villa
Keyword(s):  
Risk Factor ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Independent Risk Factor ◽  
Disease Recurrence ◽  
Short Term

Minor Depression as a Short-Term Risk Factor in Outpatients With Congestive Heart Failure

2009 ◽  
Vol 50 (5) ◽  
pp. 493-499 ◽  
Author(s):  
Chiara Rafanelli ◽  
Yuri Milaneschi ◽  
Renzo Roncuzzi
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Risk Factor ◽  
Minor Depression ◽  
Short Term

Abstract 14301: Effects of Septal Reduction Therapy on Acute Cardiovascular Events and All-cause Mortality in Patients With Obstructive Hypertrophic Cardiomyopathy: Propensity Score-matched Study

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Sae Morita ◽  
Yanling Zhao ◽  
Kohei Hasegawa ◽  
Muredach P Reilly ◽  
Mathew S Maurer ◽  
...  
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Propensity Score ◽  
New York State ◽  
Control Group ◽  
Short Term ◽  
Alcohol Septal Ablation ◽  
Septal Myectomy ◽  
All Cause Mortality ◽  
Obstructive Hypertrophic Cardiomyopathy ◽  
Matched Study

Introduction: Septal reduction therapy (SRT) - i.e., septal myectomy and alcohol septal ablation - has been used to treat medically-refractory obstructive hypertrophic cardiomyopathy (HOCM) for a few decades. However, the effects of SRT on the risk of acute cardiovascular (CV) events and all-cause mortality are largely unknown. Hypothesis: SRT is associated with a long-term decrease in acute CV events and a short-term increase in all-cause mortality in patients with HOCM. Methods: We performed a propensity score (PS)-matched study using all-payer databases that capture all hospitalizations and outpatient visits in New York State. We identified patients with HOCM who underwent SRT between January 1, 2007 and December 31, 2014 (i.e., the SRT group) and those who have never had SRT but had at least one hospitalization for HOCM during the same period (i.e., the control group). We performed 1:1 PS matching using age, sex, race/ethnicity, source of payment, season and year of starting event follow-up (i.e., the day of SRT or the index hospitalization), and Elixhauser comorbidity measures. The primary outcomes were (1) acute CV event (i.e., emergency department visit or unplanned hospitalization for CV disease) during 1-360 days and 361-720 days and (2) 7-, 15-, 30-, 180-, and 360-day all-cause mortality. We compared the risk of the outcome event using logistic regression models. Results: The analytic cohort consisted of 690 patients with HOCM (i.e., 345 PS-matched pairs). The SRT group had a lower risk of acute CV event during 361-720 days (OR 0.44; 95% CI, 0.20-0.97; P=0.04) but a higher risk of 7-day mortality (11 vs. 2 in the control group; P=0.03). The SRT group had a non-significant trend towards lower all-cause mortality in longer terms ( Figure ). Conclusion: In this population-based PS-matched study of patients with HOCM, SRT was associated with a reduced risk of acute CV events in the second post-procedure year at the sacrifice of a short-term increase in all-cause mortality.

scholarly journals Prevalence of Diastolic Dysfunction in Non Diabetic Patients of Metabolic Syndrome

2021 ◽  
Author(s):  
Kaushiki Kirty ◽  
Prabha Adhikari
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Diastolic Dysfunction ◽  
Strong Correlation ◽  
Past History ◽  
Diabetic Patients ◽  
Short Term ◽  
The Metabolic Syndrome ◽  
History Of

Abstract Background :The purpose of the present study was to study the prevalence of metabolic syndrome in non diabetic patients of metabolic syndrome Materials and Methods: 100 patients of non diabetic metabolic syndrome were screened using 2-D Echocardiogram.Results: 34% of non diabetic patients of metabolic syndrome had diastolic dysfunction, with no association found between the components of metabolic syndrome and diastolic dysfunction. There was a strong correlation between a past history of hypertension and dyslipidemia with diastolic dysfunction.Conclusion: Our findings suggest that long standing metabolic syndrome is a risk factor for diastolic dysfunction, rather than short term elevation of the metabolic syndrome parameters. Also it is likely that Diabetes and Prediabetes itself is responsible for most of the diastolic dysfunction that is seen in metabolic syndrome

Mucinous Adenocarcinoma as a High-risk Factor in Stage II Colorectal Cancer: A Propensity Score-matched Study from Japan

2020 ◽  
Vol 40 (3) ◽  
pp. 1651-1659 ◽  
Author(s):  
LIMING WANG ◽  
YASUMITSU HIRANO ◽  
GREGORY HENG ◽  
TOSHIMASA ISHII ◽  
HIROKA KONDO ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
High Risk ◽  
Propensity Score ◽  
Mucinous Adenocarcinoma ◽  
Stage Ii ◽  
High Risk Factor ◽  
Stage Ii Colorectal Cancer ◽  
Matched Study

Natalizumab-associated PML

Neurology ◽  
2017 ◽  
Vol 88 (12) ◽  
pp. 1197-1205 ◽  
Author(s):  
Nicholas Schwab ◽  
Tilman Schneider-Hohendorf ◽  
Nico Melzer ◽  
Gary Cutter ◽  
Heinz Wiendl
Keyword(s):  
Risk Factor ◽  
Risk Stratification ◽  
Treatment Duration ◽  
Jc Virus ◽  
Cumulative Risk ◽  
Current Approach ◽  
Short Term ◽  
Severe Problem ◽  
Average Treatment ◽  
Complete Treatment

Progressive multifocal leukoencephalopathy (PML) associated with natalizumab treatment continues to be a severe problem of clinically successful therapy. This is an update of risk stratification developments and discusses the current approach to depict and calculate PML incidence and PML risk. (1) PML incidence and resulting risk used in today's clinical practice are potentially outdated and the risk for patients with prior immunosuppression might have been underestimated. (2) Risk stratification according to treatment duration epochs likely suggests lower risk due to patients stopping treatment within a given epoch. PML incidence within the complete treatment epoch is statistically lowered due to the fact that patients at the beginning of an epoch presumably have a lower PML risk than the patients at the end. Periodic risk is not accurate in assessing risk for long treatment durations. (3) The JC virus (JCV) serostatus risk factor has low specificity concerning PML prediction and anti-JCV seroconversion during treatment with natalizumab further lowers its specificity over time. Specificity of the risk factor treatment duration varies depending on the average treatment duration and the number of short-term patients. These short-term patients reduce overall average treatment duration and thus enhance the specificity of the risk factor and reduce overall PML incidence. It is also suggested that short-term natalizumab patients are exclusively non-PML, even though they might still develop PML. Clinicians have to consider the cumulative risk of patients to stratify efficiently.

Sign in / Sign up

Export Citation Format

Share Document